BUPROPION

7. Becker RE & Dufresne RL: Perceptual changes with bupropion, a novel antidepressant. Am J Psychiatry 1982; 139:1200-1201.
8. Benitz WE & Tatro DS: The Pediatric Drug Handbook, 3rd ed. Mosby-Year Book Inc, Chicago, IL, 1995.
9. Briggs GG, Freeman RK & Yaffe SJ: Drugs in Pregnancy and Lactation. 5th ed. Williams and Wilkins, Baltimore, MD, 1998, p 117-18.
10. Bryant SG, Guernsey BG & Ingrim NB: Review of bupropion. Clin Pharm 1983; 2:525-537.
11. Budavari S (Ed): The Merck Index, 12th ed. Merck & Co, Inc, Whitehouse Station, NJ, 1996.
12. Chamberlain JM, Altieri MA, Futterman C et al; A prospective, randomized study comparing intramuscular midazolam with intravenous diazepam for the treatment of seizures in children. Ped Emerg Care, 1997; 13:92-94.
13. Chyka PA & Seger D: Position statement: single-dose activated charcoal. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. Clin Toxicol 1997; 35:721-736.
14. Cooper B et al: Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo. J Pharmacol Exp Ther 1980; 215:127-134.
15. David D & Esquenazi J: Rhabdomyolysis associated with bupropion treatment (letter). J Clin Psychopharm 1999; 19:185-186.
16. Davidson J: Seizures and bupropion: A review. J Clin Psychiatr 1989; 50:256-261.
17. Dufresne RL, Becker RE, Blitzer R et al: Safety and efficacy of bupropion, a novel antidepressant. Drug Devel Res 1985; 6:39-45.
18. FDA: Poison treatment drug product for over-the-counter human use; tentative final monograph. Fed Register 1985; 50:2244-2262.
19. Fresh L, Donovan W, Burkhart K et al: Bupropion toxicity causes wide complex tachycardia (abstract). J Toxicol-Clin Toxicol 1999; 37:635.
20. Gittelman DK & Kirby MG: A seizure following bupropion overdose (letter). J Clin Psychiatry 1993; 54:162.
21. Golden RN, James SP, Sherer MA et al: Psychoses associated with bupropion treatment. Am J Psychiatry 1985; 142:1459-162.
22. Golden RN, Ruderfer MV, Sherer MA et al: Bupropion in depression. I. Biochemical effects and clinical response. Arch Gen Psychiatry 1988; 45:139-143.
23. Griffith JD, Carranza J & Griffith C et al: Bupropion: clinical assay for amphetamine-like abuse potential. J Clin Psychiatr 1983; 44:206-208.
24. Harmon T, Kurta D & Krenzelok EP: Delayed seizures from sustained-release bupropion overdose (abstract). J Tox-Clin Tox 1998; 36:522.
25. Jackson CW, Head LA & Kellner CH: Catatonia associated with bupropion treatment (letter). J Clin Psychiatry 1992; 53(6):210.
26. Jacobsen LK, Chappell P & Woolston JL: Bupropion and compulsive behavior (letter). J Am Acad Child Adolesc Psychiatry 1994; 33(1):143-144.
27. Johnston AJ, Lineberry CG, Ascher JA, et al: A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry 1991; 52:450-456.
28. Jones CN, Howard JL & McBennett ST: Stimulus properties of antidepressants in the rat. Psychopharmacology 1980; 67:111-118.
29. Keren A, Tzivoni D, Gavish D et al: Etiology, warning signs and therapy of torsade de pointes: a study of 10 patients. Circulation 1981; 64:1167-1174.
30. Lahat E, Goldman M, Barr J et al: Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: prospective randomized study. BMJ 2000; 321:83-86.
31. Lai AA & Schroeder DH: Clinical pharmacokinetics of bupropion: A review. J Clin Psychiatry 1983; 44:82-84.
32. Laizure SC, DeVane CL, Stewart JT et al: Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose. Clin Pharmacol Ther 1985; 38:586-589.
33. Lazzara R: Amiodarone and torsade de pointes (editorial). Ann Intern Med 1989; 111:549-551.
34. Levenson JI: Priapism associated with bupropion treatment (letter). Am J Psychiatry 1995; 152(5):813.
35. Malesker MA, Soori GS, Malone PM et al: Eosinophilia associated with bupropion. Ann Pharmacotherapy 1995; 29:867-869.
36. Mattioni TA, Zheutlin TA, Sarmiento JJ et al: Amiodarone in patients with previous drug-mediated torsade de pointes: long-term safety and efficacy. Ann Intern Med 1989; 111:574-580.
37. Miller L & Griffith J: A comparison of bupropion, dextroamphetamine, and placebo in mixed-substance abusers. Psychopharmacology 1983; 80:199-205.
38. Paris PA & Saucier JR: ECG conduction delays associated with massive bupropion overdose. Clin Toxicol 1998; 36:595-598.
39. Peck AW, Stern WC & Watkinson C: Incidence of seizures during treatment with tricyclic antidepressant drugs and bupropion. J Clin Psychiatry 1983; 44:197-201.
40. Perticone F, Ceravolo R, Cuccurullo O et al: Prolonged magnesium sulfate infusion in the treatment of ventricular tachycardia in acquired long QT syndrome. Clin Drug Inverst 1997; 13:229-236.
41. Popli AP & Tanquary J: Antidepressant-associated seizures (letter). J Clin Psychiatry 1994; 55(6):267.
42. Preskorn SH: Antidepressant response and plasma concentrations of bupropion. J Clin Psychiatry 1983; 44:137-139.
43. Product Information Ativan(R), 1999, Wyeth-Ayerst Co, Philadelphia, PA
44. Product Information: Wellbutrin(R) Burroughs Wellcome Laboratories. Research Triangle Park, NC, January, 1986.
45. Product Information: Wellbutrin(R), bupropion. Burroughs Wellcome Co, Research Triangle Park, NC, 1989.
46. Product Information: Wellbutrin(R), bupropion. Burroughs Wellcome Co, Research Triangle Park, NC, 1999.
47. Ramcharitar V, Levine BS, Goldberger BA, et al: Bupropion and alcohol fatal intoxication: case report. Forensic Science International 1992; 56:151-156.
48. RTECS: Registry of Toxic Effects of Chemical Substances. National Institute for Occupational Safety and Health, Cincinnati, Ohio (Internet Version). Micromedex, Inc, Denver, Colorado, 2001.
49. Schroeder DH: Metabolism and kinetics of bupropion. J Clin Psychiatry 1983; 44:79-81.
50. Scott R, Besag FMC, Neville BGR: Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomized trial. Lancet 1999; 353:623-626.
51. Shrier M, Diaz JE & Tsarouhas N: Cardiotoxicity associated with bupropion overdose (letter). Ann Emerg Med 2000; 35:100.
52. Sigg T: Recurrent seizures from sustained-release bupropion. Int J Med Toxicol 1999; 2:4.
53. Smith WM & Gallagher JJ: "Les torsades de pointes": an unusual ventricular arrhythmia. Ann Intern Med 1980; 93:578-584.
54. Spiller HA, Ramoska EA, Krenzelok EP, et al: Bupropion overdose: a 3-year multi-center retrospective analysis. Am J Emer Med 1994; 12:43-45.
55. Sporer KA: The serotonin syndrome. Implicated drugs, pathophysiology and management. Drug Safety 1995; 13:94-104.
56. Storrow AB: Bupropion overdose and seizure. Am J Emerg Med 1994; 12;183-184.
57. Szuba MP & Leuchter AF: Falling backwards in two elderly patients taking bupropion. J Clin Psychiatry 1992; 53:157-159.
58. Trappler B & Miyashiro AM: Bupropion-amantadine-associated neurotoxicity (letter). J Clin Psychiatry 2000; 61:61-62.
59. Tucker WE: Preclinical toxicology of bupropion: an overview. J Clin Psychiatry 1983; 44:60-62.
60. USP DI Volume I Drug information for the health care professional. 20th edition, 2000; Micromedex Inc, World Color Book Services, Taunton, MA.
61. Vale JA: Position Statement: gastric lavage. American Academy of Clinical Toxicology/European Association of Poisons Centres and Clinical Toxicologists. Clin Toxicol 1997; 35:711-719.
62. Van Wyck Fleet J, Manberg PJ, Miller LL et al: Overview of clinically significant adverse reactions to bupropion. J Clin Psychiatry 1983; 44:191-196.
63. Vukmir RB: Torsades de pointes: a review. Am J Emerg Med 1991; 9:250-255.
64. Weiner A, Nowicki T, Bayer M et al: Zyban(R) (bupropion) overdose (abstract). J Tox-Clin Tox 1998; 36:521.
65. Wenger TL & Stern WC: The cardiovascular profile of bupropion. J Clin Psychiatry 1983; 44:176-182.

13.0 AUTHOR INFORMATION

13.1 CONTRIBUTOR(S) TO THIS DOCUMENT

A. Original publication: 09/85
B. Most recent revision: 05/01
C. List of contributors:

§ 1. Katherine M Hurlbut, MD

§ 2. Javier Waksman, MD

§ 3. Barry H Rumack, MD

§ 4. Brent R Ekins, PharmD

§ 5. POISINDEX(R) Editorial Staff

D. Specialty Board: CNS DRUGS

Refer to the POISINDEX EDITORIAL BOARD section for more information. (MG0477)

End of Document